SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
11-Mar-24 8:59 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Payment of Exercise | 4,505 | $75.12 | $338,416.00 | (3%) 139.49K to 134.98K | |
11-Mar-24 9:14 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Payment of Exercise | 4,803 | $75.12 | $360,801.00 | (5%) 103.11K to 98.3K | |
11-Mar-24 9:11 PM View: | O'Day Daniel Patrick Chairman & CEO Director | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Payment of Exercise | 13,782 | $75.12 | $1,035,300.00 | (3%) 498.63K to 484.85K | |
11-Mar-24 8:59 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Option Exercise | 9,732 | -- | -- | 8% 129.76K to 139.49K | |
11-Mar-24 9:03 PM View: | Mercier Johanna Chief Commercial Officer | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Payment of Exercise | 4,559 | $75.12 | $342,472.00 | (4%) 122.99K to 118.43K | |
12-Mar-24 4:19 PM View: | Telman Deborah H EVP, Corporate Affairs & GC | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Payment of Exercise | 846 | $75.12 | $63,551.50 | (6%) 14.6K to 13.76K | |
11-Mar-24 9:14 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Option Exercise | 10,401 | -- | -- | 11% 92.71K to 103.11K | |
12-Mar-24 3:57 PM View: | Patterson Sandra SVP, Controllership | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Payment of Exercise | 790 | $75.12 | $59,344.80 | (2%) 33.42K to 32.63K | |
11-Mar-24 9:11 PM View: | O'Day Daniel Patrick Chairman & CEO Director | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Option Exercise | 29,940 | -- | -- | 6% 468.69K to 498.63K | |
11-Mar-24 9:03 PM View: | Mercier Johanna Chief Commercial Officer | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Option Exercise | 9,844 | -- | -- | 9% 113.15K to 122.99K | |
12-Mar-24 4:19 PM View: | Telman Deborah H EVP, Corporate Affairs & GC | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Option Exercise | 2,555 | -- | -- | 21% 12.05K to 14.6K | |
12-Mar-24 3:57 PM View: | Patterson Sandra SVP, Controllership | Gilead Sciences Inc. (GILD) | 10-Mar-24 | Option Exercise | 2,682 | -- | -- | 9% 30.74K to 33.42K | |
29-Feb-24 6:35 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 29-Feb-24 | Market Sale (Planned) | 8,230 | $72.74 | $598,624.00 | (8%) 100.94K to 92.71K | < 1% |
29-Feb-24 6:35 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 28-Feb-24 | Market Sale (Planned) | 2,000 | $73.18 | $146,360.00 | (2%) 102.94K to 100.94K | 1% |
06-Feb-24 6:01 PM View: | Love Ted W Director | Gilead Sciences Inc. (GILD) | 02-Feb-24 | Grant | 512 | -- | -- | 100% 0 to 0.51K | |
02-Feb-24 2:11 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 31-Jan-24 | Payment of Exercise | 23,410 | $78.26 | $1,832,070.00 | (15%) 152.85K to 129.44K | |
02-Feb-24 2:34 PM View: | Mercier Johanna Chief Commercial Officer | Gilead Sciences Inc. (GILD) | 31-Jan-24 | Grant | 74,055 | -- | -- | 120% 61.6K to 135.66K | |
02-Feb-24 2:19 PM View: | Telman Deborah H EVP, Corporate Affairs & GC | Gilead Sciences Inc. (GILD) | 31-Jan-24 | Grant | 4,646 | -- | -- | 66% 7.08K to 11.73K | |
02-Feb-24 2:42 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 31-Jan-24 | Grant | 76,853 | -- | -- | 155% 49.47K to 126.33K | |
02-Feb-24 1:40 PM View: | O'Day Daniel Patrick Chairman & CEO Director | Gilead Sciences Inc. (GILD) | 31-Jan-24 | Grant | 230,747 | -- | -- | 73% 317.28K to 548.02K | |
02-Feb-24 2:34 PM View: | Mercier Johanna Chief Commercial Officer | Gilead Sciences Inc. (GILD) | 31-Jan-24 | Payment of Exercise | 22,509 | $78.26 | $1,761,550.00 | (17%) 135.66K to 113.15K | |
02-Feb-24 2:42 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 31-Jan-24 | Payment of Exercise | 23,709 | $78.26 | $1,855,470.00 | (19%) 126.33K to 102.62K | |
02-Feb-24 1:40 PM View: | O'Day Daniel Patrick Chairman & CEO Director | Gilead Sciences Inc. (GILD) | 31-Jan-24 | Payment of Exercise | 79,335 | $78.26 | $6,208,760.00 | (14%) 548.02K to 468.69K | |
02-Feb-24 2:11 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 31-Jan-24 | Grant | 74,961 | -- | -- | 96% 77.89K to 152.85K | |
26-Jan-24 4:31 PM View: | Telman Deborah H EVP, Corporate Affairs & GC | Gilead Sciences Inc. (GILD) | 25-Jan-24 | Option Exercise | 514 | -- | -- | 8% 6.76K to 7.28K | |
26-Jan-24 4:31 PM View: | Telman Deborah H EVP, Corporate Affairs & GC | Gilead Sciences Inc. (GILD) | 25-Jan-24 | Payment of Exercise | 194 | $80.23 | $15,564.60 | (3%) 7.28K to 7.08K | |
17-Jan-24 6:01 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 16-Jan-24 | Private Sale (Planned) | 5,000 | $85.78 | $428,900.00 | (5%) 106.53K to 101.53K | |
10-Jan-24 3:58 PM View: | Mercier Johanna Chief Commercial Officer | Gilead Sciences Inc. (GILD) | 09-Jan-24 | Private Sale (Planned) | 8,242 | $85.23 | $702,466.00 | (9%) 90.97K to 82.73K | |
11-Dec-23 7:10 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Option Exercise | 2,779 | -- | -- | 4% 70.13K to 72.91K | |
11-Dec-23 7:08 PM View: | Patterson Sandra SVP, Controllership | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Option Exercise | 518 | -- | -- | 2% 30.12K to 30.64K | |
11-Dec-23 7:04 PM View: | O'Day Daniel Patrick Chairman & CEO Director | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Option Exercise | 7,347 | -- | -- | 2% 383.69K to 391.03K | |
11-Dec-23 7:00 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Option Exercise | 2,617 | -- | -- | 2% 105.11K to 107.73K | |
11-Dec-23 7:00 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Payment of Exercise | 1,194 | $79.02 | $94,349.90 | (1%) 107.73K to 106.53K | |
11-Dec-23 7:15 PM View: | Mercier Johanna Chief Commercial Officer | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Payment of Exercise | 1,247 | $79.02 | $98,537.90 | (1%) 92.22K to 90.97K | |
11-Dec-23 7:10 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Payment of Exercise | 1,269 | $79.02 | $100,276.00 | (2%) 72.91K to 71.64K | |
11-Dec-23 7:08 PM View: | Patterson Sandra SVP, Controllership | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Payment of Exercise | 222 | $79.02 | $17,542.40 | (< 1%) 30.64K to 30.42K | |
11-Dec-23 7:04 PM View: | O'Day Daniel Patrick Chairman & CEO Director | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Payment of Exercise | 3,341 | $79.02 | $264,006.00 | (< 1%) 391.03K to 387.69K | |
11-Dec-23 7:15 PM View: | Mercier Johanna Chief Commercial Officer | Gilead Sciences Inc. (GILD) | 10-Dec-23 | Option Exercise | 2,730 | -- | -- | 3% 89.49K to 92.22K | |
13-Nov-23 6:21 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 10-Nov-23 | Payment of Exercise | 804 | $75.92 | $61,039.70 | (< 1%) 105.92K to 105.11K | |
13-Nov-23 6:21 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 10-Nov-23 | Option Exercise | 1,912 | -- | -- | 2% 104.0K to 105.92K | |
26-Oct-23 5:56 PM View: | Telman Deborah H EVP, Corporate Affairs & GC | Gilead Sciences Inc. (GILD) | 25-Oct-23 | Option Exercise | 514 | -- | -- | 8% 6.49K to 7.0K | |
26-Oct-23 5:56 PM View: | Telman Deborah H EVP, Corporate Affairs & GC | Gilead Sciences Inc. (GILD) | 25-Oct-23 | Payment of Exercise | 243 | $78.39 | $19,048.80 | (3%) 7.0K to 6.76K | |
18-Oct-23 4:31 PM View: | Dickinson Andrew D Chief Financial Officer | Gilead Sciences Inc. (GILD) | 17-Oct-23 | Private Sale (Planned) | 5,000 | $80.00 | $400,017.00 | (5%) 109.0K to 104.0K | |
13-Sep-23 6:50 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 12-Sep-23 | Private Sale (Planned) | 1,501 | $76.99 | $115,562.00 | (2%) 71.63K to 70.13K | |
11-Sep-23 8:19 PM View: | Parsey Merdad Chief Medical Officer | Gilead Sciences Inc. (GILD) | 10-Sep-23 | Payment of Exercise | 1,278 | $76.00 | $97,128.00 | (2%) 72.91K to 71.63K | |
11-Sep-23 8:44 PM View: | Mercier Johanna Chief Commercial Officer | Gilead Sciences Inc. (GILD) | 10-Sep-23 | Payment of Exercise | 1,256 | $76.00 | $95,456.00 | (1%) 90.74K to 89.49K | |
11-Sep-23 8:44 PM View: | Mercier Johanna Chief Commercial Officer | Gilead Sciences Inc. (GILD) | 10-Sep-23 | Option Exercise | 2,730 | -- | -- | 3% 88.01K to 90.74K | |
11-Sep-23 8:37 PM View: | Patterson Sandra SVP, Controllership | Gilead Sciences Inc. (GILD) | 10-Sep-23 | Payment of Exercise | 149 | $76.00 | $11,324.00 | (< 1%) 30.27K to 30.12K | |
11-Sep-23 8:37 PM View: | Patterson Sandra SVP, Controllership | Gilead Sciences Inc. (GILD) | 10-Sep-23 | Option Exercise | 519 | -- | -- | 2% 29.75K to 30.27K | |
11-Sep-23 8:11 PM View: | O'Day Daniel Patrick Chairman & CEO Director | Gilead Sciences Inc. (GILD) | 10-Sep-23 | Option Exercise | 7,348 | -- | -- | 2% 379.7K to 387.05K |